Home > Articles > Certification > Other Non-Technical

NCLEX-PN ExamPrep: Care of the Client with Hematological Disorders

This chapter discusses the most common types of hematological disorders to assist in preparing for the NCLEX-PN exam.
This chapter is from the book

This chapter is from the book

The hematologic system consists of blood, blood cells, and blood forming organs. Because the circulation of blood provides oxygen and nutrients to all body systems, a functioning hematological system is essential to health and well-being. A disorder in the system might result from a lack of function, a reduction in production, or an increase in the destruction of blood cells. This chapter reviews common disorders affecting the blood.


When anemia occurs, people have a decrease in the number of red blood cells or a decrease in the capability of these red blood cells to carry oxygen. Anemia is not a disease but is a symptom of other disorders, such as thalassemia and iron deficiency anemia. The causes of anemia are as follows:

  • Increased red blood cell destruction
  • Blood loss
  • Poor dietary iron intake
  • Poor absorption
  • Parasites

The symptoms of anemia are as follows:

  • Fatigue
  • Pallor (skin might be waxy)
  • Tachypnea
  • Cardiac changes (heart murmur, cardiomegaly)
  • Dyspnea
  • Headaches
  • Dizziness
  • Depression
  • Growth retardation
  • Late sexual maturation

Pernicious Anemia

The intrinsic factor is missing in pernicious anemia, resulting in an inability to absorb vitamin B12. Pernicious anemia is common in the elderly and clients who have had a gastric resection. It can also occur from poor dietary intake of foods containing B12, especially in vegetarian diets or those lacking dairy products. Symptoms of pernicious anemia include

  • Pallor
  • Jaundice
  • Smooth, beefy red tongue (glossitis)
  • Fatigue
  • Weight loss
  • Paresthesia
  • Diarrhea
  • Problems with proprioception (sense of position in space)

The treatment for pernicious anemia is the administration of injections of cyanocobalamin (vitamin B12). The injections are given weekly until adequate levels are reached, and then monthly for maintenance. The nurse should be aware of the following points when giving this drug:

  • Do not mix in a syringe with other medications.
  • Administer IM or deep subcutaneously.

Aplastic Anemia

Aplastic anemia is a rare disorder that occurs when there is depression of the blood-forming elements of the bone marrow. The cells are replaced with fat. Symptoms associated with aplastic anemia include

  • Decreased erythrocytes
  • Leukopenia
  • Thrombocytopenia

Aplastic anemia can be either primary (congenital) or secondary (acquired). Approximately half of all acquired cases are from unknown causes. Several factors can contribute to the development of aplastic anemia and can include

  • Drug toxicity, especially chemotherapeutic agents and the antibiotic chloramphenicol
  • Multiple blood transfusions
  • Radiation exposure
  • Autoimmune states
  • Sickle cell syndrome
  • Leukemia
  • HIV
  • Hepatitis B

Treatment of acquired aplastic anemia is accomplished by first identifying that something is preventing the bone marrow from carrying out its basic function. The focus of treatment is on the identification and removal of the offending agent. The client might also receive immunosuppressive therapies, including

  • Antilymphocyte globulin (ALG) or antithymocyte globulin (ATG)
  • Androgens
  • Cyclosporine (Sandimmune)
  • Methylprednisolone

Because of the possible fatal course that can develop from this disease, a bone marrow transplantation is also a treatment for consideration early in the disease.

Sickle Cell Anemia

Sickle cell anemia is the most common genetic disease found in the United States. It is more common in the African-American population. This disorder is inherited as autosomal recessive. A disease inherited in this manner is characterized by each parent having the sickle cell trait, resulting in a 25% chance of producing offspring with sickle cell anemia with each pregnancy.

A client with sickle cell anemia has red blood cells that have an abnormal crescent shape, as illustrated in Figure 10.1. Because they cannot flow easily through tiny capillary beds, they can become clumped, cause obstruction, and become an impairment in tissue perfusion. Red blood cells containing Hgb S are prone to sickling when exposed to decreased oxygen in the blood. After they become sickled, they are more fragile, rigid, and rapidly destroyed.

Figure 10.1

Figure 10.1 Normal and sickled red blood cells.

The most common forms of this disease in the United States are

  • Sickle cell anemia: Homozygous form (Hgb S). This is the most severe form; there is no cure.
  • Sickle cell-C disease: Heterozygous (Hgb S and Hgb C).
  • S thalassemia disease: A combination of sickle cell trait and B+–thalassemia trait (patients can still produce normal hemoglobin).

Some clients might have sickle cell trait. When this occurs a child inherits normal hemoglobin from one parent and hemoglobin S (the abnormal hemoglobin) from the other. The same defect exists as in sickle cell anemia, but only portions of the hemoglobin are Hgb S. The majority of the blood is Hgb A (normal hemoglobin). These clients might not exhibit symptoms. If these clients are exposed to low oxygen levels, symptomology and severe anemia can occur. Non-painful gross hematuria is the major complication that might occur with sickle cell trait.

The defect in sickle cell anemia can result in an obstruction in blood flow due to sickling or increased destruction of red blood cells (RBCs). Clinical manifestations of the disease are related to these defects and include

  • Splenomegaly
  • Hepatomegaly
  • Hematuria
  • Dilute urine
  • Enuresis
  • Skeletal deformities
  • Headaches
  • Aphasia
  • Seizures
  • Stroke
  • Cardiomegaly
  • Anorexia
  • Exercise intolerance
  • Hemosiderosis
  • Gallstones
  • Leg ulcers
  • Growth retardation

Several crises or exacerbations happen with sickle cell anemia. Table 10.1 outlines the types of crises associated with sickle cell anemia. The basic pathophysiology for most of the crises involves circulatory compromise in the micro circulation caused by the sickled cells. You should study this table, differentiating the types and placing primary focus on the most common type of crisis: vaso-occlusive.

Table 10.1. Sickle Cell Anemia Crises*

Type of Crisis


Associated Symptoms Include


Usually appears after the age of five. Sickling of cells results in obstruction of blood vessels, leading to a lack of oxygen to the area, which causes localized hypoxia and necrosis. It's usually not life-threatening. Hand-foot syndrome can be a result of this crisis. It is a skeletal problem that occurs in children six months to two years of age. Swelling is found in the hands and feet but usually resolves itself in two weeks.

Severe pain: Bone, abdominal, muscular, or thoracic. Jaundice, dark urine, priapism, fever, leukocytosis, lethargy, fatigue, sleepiness.


Occurs between the age of two months and five years. There is massive pooling of RBCs in the liver and spleen.

Lethargy, pale skin, hypovolemia (tachycardia, decrease in urinary output, and so on).


Results from bone marrow depression, is associated with viral infections (especially human parvovirus), and leads to RBC lysis and severe anemia.

Lethargy, pale skin, shortness of breath, altered mental status.


Rare; the result of certain drugs or infections. RBC destruction occurs.

Abdominal distention, jaundice, dark urine, reticulocytosis. If reticulocytosis occurs, it suggests some other associated problem (for example, a deficiency in glucose-6 phosphate dehydrogenase [G6PD]).


Sickled cells block major blood vessels in the brain leading to an infarction.

Neurological impairments (see Chapter 11, "Care of the Client with Disorders or the Neurological System," for clinical manifestations of a stroke).

Chest Syndrome

Similar to pneumonia; due to sickling in lung blood vessels.

Chest pain, fever, cough, anemia.

Overwhelming Infection

Especially streptococcus pneumonia, Haemophilus influenzae. It is due to a defect in spleen function. Alert: This is the number one cause of death in children under the age of five!

Symptoms of infection and septicemia (high fever, tachycardia, tachypnea, and so on).

The treatment for sickle cell anemia is twofold. The goals are to prevent sickling and treat sickle cell crises. This is accomplished by several measures, including

  • Decrease energy needs by the use of bedrest during exacerbations or crises.
  • Provide frequent rest periods during everyday activities.
  • Provide hydration.
  • Avoid contact sports due to splenomegaly.
  • Replace missing electrolytes.
  • Administer prescribed antibiotics.
  • Provide vaccination with HIB, pneumococcal, and meningococcal immunizations.
  • Administer oxygen as prescribed.
  • Monitor the administration of ordered short-term blood transfusions:
    • Packed RBC in aplastic crises, hyperhemolytic, splenic sequestration, chest syndrome, and stroke.
    • Blood is also given before major surgery to prevent anoxia and to suppress sickle cell formation.
  • A splenectomy might be performed for splenic sequestration.
  • Manage pain; apply heat to painful areas, if appropriate.
  • Assist with teaching the client to seek medical attention with signs of infection and instruct when to seek medical attention.
  • Reinforce teaching that the client should avoid high altitudes.
  • Assess vital signs.
  • Monitor intake and output.
  • Pharmacological interventions include
    • Pain medication including morphine sulfate, patient-controlled analgesia, oxycodone, Tylenol with codeine, and NSAIDs
    • Hydroxurea (Droxia)
  • Participate in reinforcing genetic counseling, including the following information:
    • Sickle cell anemia is an autosomal-recessive disorder.
    • There is a 25% chance of passing the disease to a child.
    • If a child acquires one gene, the child is also a carrier.

Iron Deficiency Anemia

There is a simple lack of iron in this disorder. It is the most prevalent nutritional disorder in the United States. The cause could be the result of poor dietary intake of iron sources. Age and financial status have an influence in this disorder with 25% of children 6–24 months of age in the low socioeconomic population having a diagnosis of anemia. Adolescents are at risk due to rapid growth needs and inadequate nutritional eating practices. Premature and multiple birth babies have reduced fetal iron supplies, making them at risk of iron deficiency anemia. Other causes are associated factors include

  • People on vegetarian diets
  • Maternal iron deficiency
  • Malabsorptive disorders
  • Diarrhea
  • Hemorrhage
  • Parasite infestations
  • B12 and folic acid deficiency

The symptoms of iron deficiency anemia are the same as general anemia. There are a few symptoms for severe, prolonged anemia that are different (included here):

  • Brittle nails
  • Cheilosis (ulcers in the corner of the mouth)
  • Sore tongue
  • Koilonchyia (concave or spoon-shaped fingernails)
  • Pica (craving to eat unusual substances such as clay or starch)

The management of iron deficiency anemia is conservative. The cause of the anemia is explored. The healthcare provider will focus on determining the source of the blood loss. A stool specimen for occult blood and endoscopic exam might be ordered to rule out these common GI sources of bleeding. A thorough menstrual history is obtained from female patients with anemia to determine whether blood loss might be the source of the anemia.

The treatment for iron deficiency anemia includes treating the underlying cause of the anemia, medications for iron replacement, client education, and administration of blood transfusions in severe cases of depletion. The drugs used during therapy include ferrous sulfate (Feosol) and iron dextran injection (Imferon).

The examinee should remember the following teaching and administration points when giving iron:

  • Administer iron preparations with orange juice to enhance absorption.
  • If giving an iron elixir, it should be administered through a straw to prevent staining the teeth.
  • When administering iron IM, it should be given through the IM Z track method.
  • Instruct the patient that her stools might be dark green or black when taking iron preparations.
  • When administering IM or IV, monitor closely for anaphylaxis.
  • Client education should focus on drug administration and side effects. The client should be instructed to increase dietary iron intake (good sources of iron include egg yolk; green, leafy vegetables; iron-fortified cereals; peanut butter; raisins; molasses; beans; oatmeal; dried fruit; and organ meats).

InformIT Promotional Mailings & Special Offers

I would like to receive exclusive offers and hear about products from InformIT and its family of brands. I can unsubscribe at any time.


Pearson Education, Inc., 221 River Street, Hoboken, New Jersey 07030, (Pearson) presents this site to provide information about products and services that can be purchased through this site.

This privacy notice provides an overview of our commitment to privacy and describes how we collect, protect, use and share personal information collected through this site. Please note that other Pearson websites and online products and services have their own separate privacy policies.

Collection and Use of Information

To conduct business and deliver products and services, Pearson collects and uses personal information in several ways in connection with this site, including:

Questions and Inquiries

For inquiries and questions, we collect the inquiry or question, together with name, contact details (email address, phone number and mailing address) and any other additional information voluntarily submitted to us through a Contact Us form or an email. We use this information to address the inquiry and respond to the question.

Online Store

For orders and purchases placed through our online store on this site, we collect order details, name, institution name and address (if applicable), email address, phone number, shipping and billing addresses, credit/debit card information, shipping options and any instructions. We use this information to complete transactions, fulfill orders, communicate with individuals placing orders or visiting the online store, and for related purposes.


Pearson may offer opportunities to provide feedback or participate in surveys, including surveys evaluating Pearson products, services or sites. Participation is voluntary. Pearson collects information requested in the survey questions and uses the information to evaluate, support, maintain and improve products, services or sites, develop new products and services, conduct educational research and for other purposes specified in the survey.

Contests and Drawings

Occasionally, we may sponsor a contest or drawing. Participation is optional. Pearson collects name, contact information and other information specified on the entry form for the contest or drawing to conduct the contest or drawing. Pearson may collect additional personal information from the winners of a contest or drawing in order to award the prize and for tax reporting purposes, as required by law.


If you have elected to receive email newsletters or promotional mailings and special offers but want to unsubscribe, simply email information@informit.com.

Service Announcements

On rare occasions it is necessary to send out a strictly service related announcement. For instance, if our service is temporarily suspended for maintenance we might send users an email. Generally, users may not opt-out of these communications, though they can deactivate their account information. However, these communications are not promotional in nature.

Customer Service

We communicate with users on a regular basis to provide requested services and in regard to issues relating to their account we reply via email or phone in accordance with the users' wishes when a user submits their information through our Contact Us form.

Other Collection and Use of Information

Application and System Logs

Pearson automatically collects log data to help ensure the delivery, availability and security of this site. Log data may include technical information about how a user or visitor connected to this site, such as browser type, type of computer/device, operating system, internet service provider and IP address. We use this information for support purposes and to monitor the health of the site, identify problems, improve service, detect unauthorized access and fraudulent activity, prevent and respond to security incidents and appropriately scale computing resources.

Web Analytics

Pearson may use third party web trend analytical services, including Google Analytics, to collect visitor information, such as IP addresses, browser types, referring pages, pages visited and time spent on a particular site. While these analytical services collect and report information on an anonymous basis, they may use cookies to gather web trend information. The information gathered may enable Pearson (but not the third party web trend services) to link information with application and system log data. Pearson uses this information for system administration and to identify problems, improve service, detect unauthorized access and fraudulent activity, prevent and respond to security incidents, appropriately scale computing resources and otherwise support and deliver this site and its services.

Cookies and Related Technologies

This site uses cookies and similar technologies to personalize content, measure traffic patterns, control security, track use and access of information on this site, and provide interest-based messages and advertising. Users can manage and block the use of cookies through their browser. Disabling or blocking certain cookies may limit the functionality of this site.

Do Not Track

This site currently does not respond to Do Not Track signals.


Pearson uses appropriate physical, administrative and technical security measures to protect personal information from unauthorized access, use and disclosure.


This site is not directed to children under the age of 13.


Pearson may send or direct marketing communications to users, provided that

  • Pearson will not use personal information collected or processed as a K-12 school service provider for the purpose of directed or targeted advertising.
  • Such marketing is consistent with applicable law and Pearson's legal obligations.
  • Pearson will not knowingly direct or send marketing communications to an individual who has expressed a preference not to receive marketing.
  • Where required by applicable law, express or implied consent to marketing exists and has not been withdrawn.

Pearson may provide personal information to a third party service provider on a restricted basis to provide marketing solely on behalf of Pearson or an affiliate or customer for whom Pearson is a service provider. Marketing preferences may be changed at any time.

Correcting/Updating Personal Information

If a user's personally identifiable information changes (such as your postal address or email address), we provide a way to correct or update that user's personal data provided to us. This can be done on the Account page. If a user no longer desires our service and desires to delete his or her account, please contact us at customer-service@informit.com and we will process the deletion of a user's account.


Users can always make an informed choice as to whether they should proceed with certain services offered by InformIT. If you choose to remove yourself from our mailing list(s) simply visit the following page and uncheck any communication you no longer want to receive: www.informit.com/u.aspx.

Sale of Personal Information

Pearson does not rent or sell personal information in exchange for any payment of money.

While Pearson does not sell personal information, as defined in Nevada law, Nevada residents may email a request for no sale of their personal information to NevadaDesignatedRequest@pearson.com.

Supplemental Privacy Statement for California Residents

California residents should read our Supplemental privacy statement for California residents in conjunction with this Privacy Notice. The Supplemental privacy statement for California residents explains Pearson's commitment to comply with California law and applies to personal information of California residents collected in connection with this site and the Services.

Sharing and Disclosure

Pearson may disclose personal information, as follows:

  • As required by law.
  • With the consent of the individual (or their parent, if the individual is a minor)
  • In response to a subpoena, court order or legal process, to the extent permitted or required by law
  • To protect the security and safety of individuals, data, assets and systems, consistent with applicable law
  • In connection the sale, joint venture or other transfer of some or all of its company or assets, subject to the provisions of this Privacy Notice
  • To investigate or address actual or suspected fraud or other illegal activities
  • To exercise its legal rights, including enforcement of the Terms of Use for this site or another contract
  • To affiliated Pearson companies and other companies and organizations who perform work for Pearson and are obligated to protect the privacy of personal information consistent with this Privacy Notice
  • To a school, organization, company or government agency, where Pearson collects or processes the personal information in a school setting or on behalf of such organization, company or government agency.


This web site contains links to other sites. Please be aware that we are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of each and every web site that collects Personal Information. This privacy statement applies solely to information collected by this web site.

Requests and Contact

Please contact us about this Privacy Notice or if you have any requests or questions relating to the privacy of your personal information.

Changes to this Privacy Notice

We may revise this Privacy Notice through an updated posting. We will identify the effective date of the revision in the posting. Often, updates are made to provide greater clarity or to comply with changes in regulatory requirements. If the updates involve material changes to the collection, protection, use or disclosure of Personal Information, Pearson will provide notice of the change through a conspicuous notice on this site or other appropriate way. Continued use of the site after the effective date of a posted revision evidences acceptance. Please contact us if you have questions or concerns about the Privacy Notice or any objection to any revisions.

Last Update: November 17, 2020